Ovariumcarcinoom, fase II, BRCAwt, UV1-olaparib-durvalumab
Ovarium, endometrium, TNBC, fase I, B7H4xCD3 bispecifiek antilichaam
Ovariumcarcinoom, peritoneale kanker, fase I/II, hoog CA-125, cemiplimab and MUC16-antibody
Solide tumoren, fase 1, MET, MET kinase inhibitor
Mamma, borst, fase III, PIK3CA, trastuzumab + alpelisib +/- fulvestrant
Solide tumoren, fase 1, NY-ESO-1-positief, Precious-01 nanodeeltje
T4N0 (hoog risico Stadium II) of Stadium III resectabel coloncarcinoom; fase 3; dMMR/MSI-H; Perioperatief Dostarlimab monotherapie versus standaard zorg
Hoogrisico niercelcarcinoom, fase III, adjuvante immuuntherapie
HNSCC, fase I/II, CPS≥1, petosemtamab
Sarcomen, fase I, radiotherapie, DDR remmers
Deze website maakt gebruik van cookies.
